AstraZeneca’s plans to get an amyloidosis drug to market look further out of reach after the pharma’s anti-fibril antibody failed to reduce deaths and hospitalizations in a key phase 3 study. | ...

The primary endpoint was functional immune tolerance, defined as off all immunosuppressive drugs 24 months after ...

Techcyte is proud to share results from a published pilot study demonstrating the effectiveness of its AI-powered kidney ...

Recurrent lupus nephritis post-transplant may go undetected without surveillance biopsies. This study reveals high recurrence ...

In comparative analysis, EchoGo® Amyloidosis outperformed two validated clinical scoring systems, the Transthyretin Cardiac ...

ApoCII amyloidosis, resulting from abnormal organ deposition of toxic fibrillar amyloid proteins, is an ultra-rare condition that mostly affects the kidneys and manifests with protein spillage into th ...

Among 83 patients receiving biologic agents for their underlying conditions and who had serum amyloid-α (AA) amyloidosis affecting the kidneys, from 60% to 88% did not develop end-stage renal ...

3-Hydroxyquinolin-2-Ones Act as Dual Inhibitors of Ferroptosis and Monoamine Oxidase B: Reducing Alzheimer’s Disease-Related Amyloid Precursor Protein and Hyperphosphorylated Tau In Vivo ...

1 Introduction Histopathological analysis of kidney biopsies plays a pivotal role in diagnosing and monitoring chronic kidney diseases, where precise segmentation of functional tissue units (FTUs), ...